Treatment investigated to prevent blood-clotting disordersA new subcutaneous therapy could offer a promising solution to a bleeding disorder in both children and adults.
Specialty drug pipeline predictions: Seven key areas to watchThe specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.
Bleeding disorders: When to worry, how to helpStudies have shown that 1 in 5 women who consult their doctor for heavy or prolonged bleeding during their periods actually have an underlying bleeding disorder.
New antibody eases hemophilia treatmentA new antibody eases treatment of severe hemophilia A.
New biologic to control bleeding for hemophilia B patientsAt the end of April, FDA approved a new biologic to help prevent and control bleeding in patients with hemophilia B who are 12 years and older. It also is approved for use in perioperative management in this patient population.
FDA approves NovoSeven RT for Glanzmann's thrombastheniaFDA approved coagulation factor VIIa [recombinant] (NovoSeven RT, Novo Nordisk), for the treatment of Glanzmann’s thrombasthenia, a rare genetic bleeding disorder.
FDA drug approvals: January 2014FDA approvals, complete response, fast-track designations, priority review, first-time generic approval
FDA actions in brief
Managing heavy menstrual bleeding in adolescentsDiagnosis and treatment involve ruling out bleeding disorders and determining the appropriate management modalities.
FDA approves new hemophilia drugFDA has approved Coagulation Factor IX (Recombinant) (Rixubis, Baxter International) for routine prophylactic treatment, control of bleeding episodes, and perioperative management in adults with hemophilia B.